AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Looking ahead, Novo Nordisk’s pipeline includes several promising candidates that could further strengthen its position in the metabolic disease space. Amycretin, a once-daily oral GLP-1/Amylin ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...

Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma A/S (CSE:ZELA).

Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety profile similar to ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...

but Novo Nordisk is banking on a dual mode of action that includes amylin for its next generation of drugs, with experimental compounds called amycretin and CagriSema. Disappointing clinical trial ...

Novo Nordisk has been developing next-generation therapies that combine GLP-1 with amylin. Its experimental candidates, amycretin and CagriSema, aim to improve weight loss outcomes through a dual ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...